PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS

Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R Confirmation that…